Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06230770

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

The Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating Testosterone Therapy for Gender Affirmation

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
160 (estimated)
Sponsor
University of California, San Diego · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBleeding dataParticipants will report their daily bleeding patterns

Timeline

Start date
2024-02-01
Primary completion
2025-06-10
Completion
2026-12-31
First posted
2024-01-30
Last updated
2025-07-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06230770. Inclusion in this directory is not an endorsement.